Abstract
Proteins of the tumour necrosis factor (TNF) family are implicated in the regulation of essential cell processes such as proliferation, differentiation, survival and cell death. Altered expression of TNF family members is often associated with pathological conditions such as autoimmune disease and cancer. The TNF-like ligand APRIL (A PRoliferation Inducing Ligand), first described in 1998, was named for its capacity to stimulate tumour cell proliferation in vitro. APRIL expression was initially reported in haematopoietic cells in physiological conditions, and it is overexpressed in certain tumour tissues. APRIL is now known to be involved in activation and immune responses of B cells, as well as in B cell malignancies. This review focuses on recent advances in understanding APRIL and its receptors in physiology and tumour pathology, including the accumulating evidence that specific Toll-like receptor ligands can trigger APRIL-mediated responses, and the identification of new sources of APRIL such as epithelial cells and tumour- infiltrating neutrophils.
Keywords: APRIL, BLyS, BAFF, immunity, B-cell malignancies, tumours, lymphoma
Current Molecular Medicine
Title: The Expanding Role of APRIL in Cancer and Immunity
Volume: 8 Issue: 8
Author(s): Lourdes Planelles, Jan Paul Medema, Michael Hahne and Gijs Hardenberg
Affiliation:
Keywords: APRIL, BLyS, BAFF, immunity, B-cell malignancies, tumours, lymphoma
Abstract: Proteins of the tumour necrosis factor (TNF) family are implicated in the regulation of essential cell processes such as proliferation, differentiation, survival and cell death. Altered expression of TNF family members is often associated with pathological conditions such as autoimmune disease and cancer. The TNF-like ligand APRIL (A PRoliferation Inducing Ligand), first described in 1998, was named for its capacity to stimulate tumour cell proliferation in vitro. APRIL expression was initially reported in haematopoietic cells in physiological conditions, and it is overexpressed in certain tumour tissues. APRIL is now known to be involved in activation and immune responses of B cells, as well as in B cell malignancies. This review focuses on recent advances in understanding APRIL and its receptors in physiology and tumour pathology, including the accumulating evidence that specific Toll-like receptor ligands can trigger APRIL-mediated responses, and the identification of new sources of APRIL such as epithelial cells and tumour- infiltrating neutrophils.
Export Options
About this article
Cite this article as:
Planelles Lourdes, Medema Paul Jan, Hahne Michael and Hardenberg Gijs, The Expanding Role of APRIL in Cancer and Immunity, Current Molecular Medicine 2008; 8 (8) . https://dx.doi.org/10.2174/156652408786733711
DOI https://dx.doi.org/10.2174/156652408786733711 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Pathophysiology of Thrombosis and Potential Targeted Therapies in Antiphospholipid Syndrome
Current Vascular Pharmacology Dendritic Cell Homeostasis in the Regulation of Self-Reactivity
Current Pharmaceutical Design Prebiotics and Probiotics in Inflammatory Bowel Disease: Where are we now and where are we going?
Current Clinical Pharmacology Reactive Oxygen Species in the Initiation of IL-4 Driven Autoimmunity as a Potential Therapeutic Target
Current Pharmaceutical Design Emerging Indications for Statins: A Pluripotent Family of Agents with Several Potential Applications
Current Pharmaceutical Design Mouse Models of Autoimmune Diseases - Autoimmune Myocarditis
Current Pharmaceutical Design The Potential of Selected Prostanoid Receptors as Targets in a New Therapeutic Strategy for Allergy and Immune Diseases
Current Drug Safety Celastrol Inhibits Inflammatory Stimuli-Induced Neutrophil Extracellular Trap Formation
Current Molecular Medicine Role of C1858T Polymorphism of Lymphoid Tyrosine Phosphatase in Egyptian Children and Adolescents with Type 1 Diabetes
Current Diabetes Reviews Nanotechnology in Therapeutics – Current Technologies and Applications
Current Nanoscience Clinical Applications of Autoimmunity to Citrullinated Proteins in Rheumatoid Arthritis, from Improving Diagnostics to Future Therapies
Recent Patents on Inflammation & Allergy Drug Discovery Novel Topical Nanocarriers for Treatment of Psoriasis: An Overview
Current Pharmaceutical Design The Immunosuppressive Role of Adenosine A2A Receptors in Ischemia Reperfusion Injury and Islet Transplantation
Current Diabetes Reviews S1P Receptor Modulators in Cell Trafficking and Therapeutics
Current Immunology Reviews (Discontinued) Biochemical Markers of Autoimmune Diseases of the Nervous System
Current Pharmaceutical Design Protein Kinases as Drug Targets in Human and Animal Diseases
Current Enzyme Inhibition Recent Patents on the Treatment of Type 1 Diabetes
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Pancreatic Islet Transplantation in Type 1 Diabetes Mellitus: An Update on Recent Developments
Current Diabetes Reviews The Antinflammatory Effect of Alpha-MSH in Skin: A Promise for New Treatment Strategies
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Estrogen, A Double-Edged Sword: Modulation of TH1- and TH2-Mediated Inflammations by Differential Regulation of TH1 / TH2 Cytokine Production
Current Drug Targets - Inflammation & Allergy